These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8516727)

  • 1. [Recombinant factor VIII].
    Tusell JM
    Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant clotting factor concentrates.
    Lusher JM
    Baillieres Clin Haematol; 1996 Jun; 9(2):291-303. PubMed ID: 8800506
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Abildgaard CF
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):44. PubMed ID: 1908127
    [No Abstract]   [Full Text] [Related]  

  • 4. [The current therapeutic bases for hemophilia].
    Négrier C
    Transfus Clin Biol; 2000 Jun; 7(3):257-8. PubMed ID: 10919215
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of recombinant factor VIII on hemophilia care.
    Mannucci PM
    Vox Sang; 1994; 67 Suppl 3():49-52. PubMed ID: 7975511
    [No Abstract]   [Full Text] [Related]  

  • 7. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 8. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 9. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 12. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 13. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 15. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant blood clotting proteins for hemophilia therapy.
    Limentani SA; Roth DA; Furie BC; Furie B
    Semin Thromb Hemost; 1993; 19(1):62-72. PubMed ID: 8456325
    [No Abstract]   [Full Text] [Related]  

  • 18. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate).
    Ingerslev J; Christiansen K; Ravn HB; Bray GL; Gomperts ED;
    Thromb Haemost; 2002 Apr; 87(4):626-34. PubMed ID: 12008945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.